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Introduction: There is evidence that interferon is involved in the pathogenesis of primary Sjögren’s syndrome
(pSS). The interferon-inducible IFI16 protein, normally expressed in cell nuclei, may be overexpressed, mislocalized in
the cytoplasm and secreted in the extracellular milieu in several autoimmune disorders. This leads to tolerance
breaking to this self-protein with consequent development of anti-IFI16 antibodies. The aim of this study was to
identify the pathogenic and clinical significance of IFI16 and anti-IFI16 in pSS.
Methods: IFI16 and anti-IFI16 were assessed in the serum of 67 pSS patients and over 100 healthy donors by
enzyme-linked immunosorbent assay. IFI16 was also evaluated by immunohistochemistry in minor salivary glands of
15 pSS patients and 10 subjects with sicca symptoms but without any clinical, serological or histological features of pSS.
Results: pSS patients display higher serum levels of both IFI16 and anti-IFI16 compared to healthy donors. IFI16
concentration was directly correlated with disease duration and focus score and inversely correlated with age at
diagnosis. Moreover, IFI16 positivity was associated with concurrent positivity for rheumatoid factor. Interestingly, the
direct correlation between IFI16 positivity and focus score was independent of disease duration and age at diagnosis.
pSS minor salivary glands display marked expression and cytoplasmic mislocalization of IFI16 by acinar and ductal
epithelial cells as well as infiltrating lymphocytes and peri/intralesional endothelium compared to minor salivary glands
with normal architecture or nonspecific chronic sialadenitis. Within the mononuclear cell infiltrate, IFI16 expression
appears to parallel the distribution of T lymphocytes.
Conclusion: Our data suggest that the IFI16 protein may be involved in the pathogenesis of glandular inflammation
occurring in pSS.Introduction
Primary Sjögren’s syndrome (pSS) is a chronic systemic
autoimmune disease that primarily affects exocrine
glands. Clinical presentation considerably varies from
relatively mild sicca symptoms to severe systemic in-
volvement, with an increased risk of developing non-
Hodgkin’s lymphoma [1]. Classically, minor salivary glands
(MSGs) of patients with pSS show a focal lymphocytic
sialadenitis (FLS) characterized by the presence of
lymphocyte aggregates usually located in perivascular* Correspondence: roberto.gerli@unipg.it
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logical damage ranges from mild to diffuse infiltrates
with progressive loss of normal glandular tissue. T cells
predominate in mild lesions, whereas B cells are the
most represented cell subset in the advanced lesions.
The infiltrating lymphocytes are often organized into
tertiary lymphoid tissues in nonlymphoid locations, also
known as ectopic lymphoid structures, showing a net-
work including specific segregated T- and B-cell zones
and follicular dendritic cells. Some of these tertiary
lymphoid tissues are arranged in germinal centers
(GCs) [2]. To date, the pathogenesis of pSS is not fully
elucidated. However, a growing number of studies sug-
gest that the so-called interferon (IFN) signature is in-
volved in the induction and perpetuation of the diseasele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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marked upregulation of type I IFN-regulated gene tran-
scripts, described in pSS patients as well as in animal
models of the disease, suggest a strong response due
to glandular apoptosis and toll-like receptor activation
[5–7]. In this context, the interferon gamma-inducible
protein 16 (IFI16), a member of the HIN200/Ifi200
family of IFN-inducible genes, has been drumming up
growing interest for its possible role in initiation and
progression of chronic inflammatory autoimmune dis-
orders. IFI16 is constitutively expressed in the nucleus
of hematopoietic cells, particularly lymphocytes, vas-
cular endothelial cells and keratinocytes [8]. Although
it is a multifaceted protein involved in cell cycle regu-
lation, tumor suppression, endothelial cell apoptosis
and DNA damage signaling [9–12], great interest is
derived from the evidence that its overexpression may
drive early steps of an inflammatory response through
nuclear factor-kB-mediated secretion of pro-inflammatory
molecules. In this context, it is important to note that IFI16,
normally expressed in cell nuclei, may be overexpressed in
several autoimmune disorders. Its overexpression, cytoplas-
mic mislocalization and extracellular appearance during cell
death lead to the breaking of tolerance to this self-protein
with consequent development of anti-IFI16 antibodies
[13]. Therefore, the release of IFI16 in the extracellular
milieu may mark the first step in the development of
autoimmunity [14]. The presence of significant levels of
extracellular IFI16 protein and anti-IFI16 antibodies have
been recently identified in the sera of patients affected by
different systemic autoimmune diseases, including pSS
[10, 12, 15–17], thereby confirming its presence in the
extracellular milieu and its possible role as an autoantigen
[14]. Taken together, these data provide evidence for a
novel alarmin function of IFI16 protein which can be
overexpressed upon inflammatory stimuli and released
in the extracellular environment with eventual endothe-
lial cell binding causing tissue damage. However, a
number of questions regarding the role of IF16 are still
open. Thus, we were prompted to analyze possible
pathogenic, diagnostic and prognostic significance of
IFI16 protein and anti-IFI16 antibodies in patients with
pSS, a combined model of systemic autoimmune and
chronic inflammatory disorder.
Methods
Patients
Sixty-seven consecutive female patients with pSS, classi-
fied according to the European–American criteria [18],
with a mean age of 59 years (standard error of the mean
(SEM) = 1.5) were enrolled. At the time of enrollment,
serum samples were collected and stored at −20 °C until
use and clinical and serological features were recorded.
Concerning hematological abnormalities, leukopenia wasdefined as ≤3000 leukocytes/mL, hypergammaglobuline-
mia was defined as an IgG level over 16 g/L and hypo-
complementemia was defined by a reduction of C4 or
C3. One-hundred and eighty two healthy blood donors,
145 females and 37 males, with a mean age of 51 years
(SEM = 1.2) acted as controls (healthy donors; HDs). Fif-
teen pSS MSGs, collected at the time of diagnosis, were
also retrospectively evaluated. Ten MSGs obtained from
subjects with sicca symptoms, but without any clinical
and serological features of pSS, acted as controls (five
normal MSGs and five showing different grades of non-
specific chronic sialadenitis (NSCS), without FLS). The
whole study was approved by the local Ethics Committee
(Comitato Etico delle Aziende Sanitarie dell’Umbria, CEAS)
and written informed consent was obtained in accordance
with the declaration of Helsinki.
Determination of extracellular IFI16 protein by capture
ELISA
A capture enzyme-linked immunosorbent assay (ELISA)
was employed for determination of circulating extracellu-
lar IFI16 protein following a procedure detailed elsewhere
[15]. Briefly, polystyrene micro-well plates (Nunc-Immuno
MaxiSorp; Nunc, Roskilde, Denmark) were coated with
a home-made polyclonal rabbit-anti-IFI16 antibody (aa
478–729). Subsequently, the plates were washed and
free binding sites were saturated with phosphate-buffered
saline (PBS)/0.05 % Tween/3 % bovine serum albumin
(BSA). After blocking, sera were added in duplicate. Puri-
fied 6His-IFI16 protein was used as standard. BSA served
as negative control. The samples were washed and in
each case monoclonal mouse anti-IFI16 antibody (Santa
Cruz, sc-8023) was added and incubated for 1 h at
room temperature. After washing, horseradish peroxidase-
conjugated anti-mouse antibody (GE Healthcare Europe
GmbH, Milan, Italy) was added. Following the addition of
the substrate (TMB; KPL, Gaithersburg, MD, USA),
absorbance was measured at 450 nm using a micro-
plate reader (SpectraCount, Packard, Packard BioScience
Company). The determination of the concentration was
carried out using a standard curve for which increasing
concentrations of purified 6His-IFI16 were used.
Determination of antibody titers towards human
recombinant IFI16 by ELISA
To detect anti-IFI16 antibodies, polystyrene micro-well
plates (Nunc-Immuno MaxiSorp; Nunc) were coated with
a solution of recombinant IFI16 in PBS and, after blocking,
sera were added in duplicate. After washing, horseradish
peroxidase-conjugated rabbit anti-human IgG (Dako
Cytomation, Carpinteria, CA, USA) was added. Following
the addition of the substrate (TMB; KPL), absorbance
was measured at 450 nm using a microplate reader
(SpectraCount, Packard). The background reactivity of
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sults. A standard curve was constructed by serially dilut-
ing IgG from an anti-IFI16-positive patient serum [16, 17].
Histological analysis of MSG biopsies
Labial MSG specimens were obtained from 15 pSS pa-
tients and 10 HDs according to international guidelines.
All sections were randomly analyzed by two expert ob-
servers, blinded to clinical and laboratory data. Each
sample was independently evaluated and any discrepan-
cies were resolved by consensus. The histological pattern
(normal, NSCS, FLS) was assessed using hematoxylin-eosin
stained sections [19, 20]. FLS pattern, which is diagnostic
for pSS, is characterized by the presence of at least one
focus, namely an aggregate of at least 50 lymphocytes, in
the glandular tissue. NSCS pattern is characterized by
scattered lymphocyte aggregates that do not reach the
number of 50 cells and therefore cannot be classified as
foci.
Both cellular infiltrate and lymphoid organization, in-
cluding the presence of GC-like structures, were assessed
by immunofluorescence staining of sequential sections
with monoclonal antibodies recognizing CD3, CD20
and CD21 (all provided by DakoCytomation, Glostrup,
Denmark), as previously described [2, 21].
IFI16 expression was evaluated using standard immu-
nohistochemistry, as already described in a previous study
[13]. Images were acquired using an Olympus BX53 fluor-
escence microscope with CellSens software (Olympus
America Inc., Center Valley, PA, USA).
Statistical analysis
Data analysis was performed using IBM-SPSS version
13.0 (IBM, Armonk, NY, USA). Mann Whitney U test or
Chi square test were employed to compare variables
among subgroups. Binary logistic regression was used toFig. 1 Expression of interferon gamma-inducible (IFI16) protein (a) and an
spectively) and primary Sjögren’s syndrome (pSS) patients (n = 67). Bars in
termined as the 95th percentile of the control population. p values wereidentify possible association between clinical and sero-
logical features and the presence of serum IFI16 protein
and anti-IFI16 antibody. The significance level was two
sided and set at p < 0.05.
Results
Serum IFI16 protein and anti-IFI16 antibody detection
As shown in Fig. 1, serum levels of both IFI16 protein
and anti-IFI16 antibodies were higher in pSS than in HDs
(p < 0.05 and p < 0.0001, respectively). According to a
cut-off established as the 95th percentile of the control
population, positivity for IFI16 protein and for anti-IFI16
was considered for values ≥27 ng/ml and ≥113 U/ml, re-
spectively. IFI16 was significantly more prevalent in pSS
compared to HDs as it was detectable in 14/67 patients
(21 %) and in 6/116 HDs (5 %) (p < 0.0001). Similarly, a
significantly higher prevalence in pSS was confirmed
also for anti-IFI16 antibodies that were present in 23/67
pSS patients (34 %) and in 9/182 HDs (5 %) (p < 0.0001).
Clinical and laboratory associations with serum IFI16
protein and anti-IFI16 antibodies
Table 1 summarizes clinical and serological features in the
overall pSS patient population and in patients subdivided
according to the presence or absence of serum IFI16/anti-
IFI16. We failed to observe any differences among sub-
groups except for a higher prevalence of rheumatoid
factor (RF) in IFI16+ patients. We subsequently evalu-
ated whether IFI16 serum concentration, rather than its
presence, could be correlated to any clinical variable. A
direct correlation with disease duration (Spearman’s rho =
0.32; p = 0.008) and an inverse correlation with age at
diagnosis (Spearman’s rho = 0.24; p = 0.04), without
any association with patients’ age, were observed (data
not shown). Interestingly, all IFI16+ patients displayed
a disease duration >3 years. No association betweenti-IFI16 antibodies (b) in healthy donors (HD; n = 116 and n = 182, re-
dicate mean values. Dotted lines mark cut-off levels of positivity de-
calculated with Mann Whitney U test
Table 1 Demographic, clinical and serological characteristics of pSS patients
All pSS IFI16 neg IFI16 pos p anti-IFI16 neg anti-IFI16 pos p
Patient number (n) 67 53 14 – 44 23 –
Age (years)a 59 ± 1 60 ± 2 55 ± 3 0.2 60 ± 2 56 ± 2 0.2
Age at diagnosis (years)a 49 ± 2 50 ± 2 45 ± 3 0.3 51 ± 2 46 ± 2 0.3
Disease duration (years)a 9 ± 1 9 ± 1 10 ± 1 0.1 9 ± 1 10 ± 2 0.1
Xerophtalmia 92.5 94.3 85.7 0.3 86.4 82.6 0.7
Xerostomia 85.1 88.7 71.4 0.2 90.9 95.7 0.6
Salivary gland swelling 47.8 49.1 42.9 0.8 50.0 43.5 0.8
Extraglandular manifestationsb 76.1 77.3 71.4 0.7 79.5 69.5 0.4
Leukopenia 37.3 37.7 35.7 0.9 38.6 34.8 0.8
Hypergammaglobulinemia 61.2 56.6 78.6 0.2 61.4 60.9 0.8
Hypocomplementemia 26.9 22.6 42.9 0.2 25.0 30.4 0.7
Autoantibodies
Neither anti-SSA nor anti-SSB 16.4 17.0 14.3 0.9 18.2 13 0.7
Anti-SSA only 26.9 28.3 21.4 0.7 20.5 39.1 0.1
Anti-SSA and anti-SSB 56.7 54.7 64.3 0.6 61.4 47.8 0.3
RF ± anti-SSA ± anti-SSB 68.7 60.4 100 0.003 70.5 65.2 0.8
aValues are reported as mean ± standard error of the mean and corresponding p values are calculated with Mann Whitney U test. All other values are reported as
percentage of patients and corresponding p values are calculated with chi square test. bPercentage of patients with at least one extraglandular manifestation
including articular, pulmonary or esophageal involvement, purpura, Raynaud’s phenomenon and lymphadenopathy. IFI16 interferon gamma-inducible protein 16,
neg negative, pos positive, pSS primary Sjögren’s syndrome, RF rheumatoid factor
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calculated with the EULAR Sjögren’s syndrome disease
activity index, was observed. Finally, no correlations
between anti-IFI16 antibody positivity or titer and any
clinical and/or serological parameters were identified.
Histological evaluation of IFI16 protein at glandular level
The histological analysis of normal MSGs revealed that
IFI16 protein was not constitutively expressed by glan-
dular tissue (Fig. 2a). Conversely, few nuclei of glandular
epithelial cells were positive for IFI16 staining in NSCS.
A cytoplasmic localization of this protein could be only
occasionally detected in glandular epithelial cells (Fig. 2b).
In this context, IFI16 was also displayed by the nuclei of
inflammatory mononuclear cells (Fig. 2b). The scattered
or small aggregates of plasma cells, normally present in
MSGs or during NSCS, appeared to have nuclei with a
lower IFI16 positivity when compared with other in-
flammatory cells. In contrast, in pSS biopsies intense
IFI16-positive nuclei were found in both ductal and acinar
epithelial cells. A stronger cytoplasmic staining with re-
spect to normal and NSCS was detected in ductal epi-
thelial cells, while the detection of IFI16 staining in the
cytoplasm of acinar epithelial cells was hampered by
abundant secretion products (Fig. 2a–c). IFI16 nuclear
and cytoplasmic staining was also observed in the inflam-
matory cells involved in FLS (Fig. 2c). A more detailed
analysis of inflammatory infiltrate, according to the distri-
bution of T and B lymphocytes and the presence of GCs,showed a predominance of IFI16 staining in the T- rather
than B-cell area containing GC-like structures (Fig. 2e).
This particular IFI16 distribution, paralleling B/T cell seg-
regation, was also detectable in the inflammatory follicles
of tonsil specimens (Fig. 2d and f ). Concerning the nu-
clear staining for IFI16 in endothelial cells, our results
showed that the constitutional expression of IFI16 was
more pronounced in pSS FLS peri- and intralesional
endothelium compared to normal and NSCS patterns
(Fig. 2a–c, inserts).Correlations between IFI16 protein serum levels and
glandular infiltration degree
Taking the aforementioned observations in the serum
and in MSGs, we attempted to identify a possible associ-
ation between circulating IFI16 and histological features.
The median focus score (FS), namely the number of foci
in 4 mm2 of glandular tissue, was 3.5 (range 0–12). We
observed that IFI16 concentration was directly correlated
with the FS at the time of diagnosis (Spearman’s rho =
0.30; p = 0.02). Furthermore, this association was quanti-
fied by binary logistic regression that revealed an odds
ratio of 1.4 (95 % confidence interval 1.03 to 1.9; p = 0.03)
for the FS. However, since also disease duration and age at
diagnosis were found to be correlated with IFI16, we
corrected the analysis according to these variables and
observed that FS was associated with serum IFI16 inde-
pendently off disease duration and age at diagnosis
Fig. 2 Expression of IFI16 in MSG and tonsil. Immunohistochemical analysis for IFI16 in MSG with normal architecture (a), NSCS (b), FLS (c) and in
tonsil (d). Inserts in a, b and c depict a detail of endothelial cells from the corresponding panel. e, f Double immunofluorescence staining for CD3
(red) and CD20 (green) in FLS (e) and tonsil (f). Insert in e depicts immunofluorescence staining for CD21 (green) and DAPI (blue), representing a
GC-like structure in the CD20+ B-cell area of panel e
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p = 0.04).
Discussion
Several data from animal models and patients highlighted
the pathogenic role of the IFN signature in pSS [6, 7],
thereby supporting the evaluation of the IFN-inducible
gene role as an intriguing issue. In the present study, we
confirmed that patients with pSS display circulating IFI16
as well as antibodies reactive against this protein. More
interestingly, however, our data appear to suggest that the
IFI16 protein may be involved in the development of
glandular inflammation occurring in pSS. In fact, unlikenormal and NSCS MSGs, a marked expression of this
molecule by acinar and ductal epithelial cells as well as
infiltrating lymphocytes and peri/intralesional endothe-
lium was found in pSS MSGs.
In recent years, a better understanding of pSS patho-
genesis has allowed the identification of salivary gland
epithelial cells (SGECs) as active players rather than in-
nocent bystanders in the initiation and perpetuation of the
disease [22]. In particular, following IFN ligation to toll-
like receptors (TLRs), such as TLR3, SGECs upregulate
and mislocalize nuclear proteins in the cytoplasm that
are normally segregated from the immune system. These
autoantigens, including Ro52 and Ro60, are subsequently
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or following SGEC apoptosis [23]. The consequence of
these events trigger activation of T lymphocytes and an
antigen-specific B-cell recruitment leading to the produc-
tion of autoantibodies, such as anti-Ro52 and anti-Ro60,
key elements of pSS classification criteria [18].
This scenario appears to fit with our findings concern-
ing IFI16 at the glandular level, where the predominant
chronic inflammatory process takes place, and anti-IFI16
in the bloodstream. Therefore, it is reasonable to specu-
late that IFI16 may undergo the same fate as the afore-
mentioned Ro52 and Ro60 nuclear proteins in SGECs.
Of interest, in addition, similarly to anti-Ro52 and anti-
Ro60 autoantibodies, those against IFI16 are also displayed
by some, but not all, pSS patients.
Finally, it is worth mentioning that while some epi-
thelial tissues, including skin, gastrointestinal tract,
urogenital tract, and glands and ducts of breast tissues
constitutively express IFI16 [8], normal MSGECs do
not display the IFI16 protein. This observation under-
scores that IFI16 overexpression observed in NSCS and,
to a greater extent, in pSS results from a “de novo” synthe-
sis of such a protein. The presence of free IFI16 protein in
the serum could reflect cell secretion of the protein in the
extracellular milieu. The fact that we were able to detect
the protein in the serum from only a subgroup of patients
is not so surprising, since it is conceivable that the main
pathogenic role of IFI16 is exerted at the glandular tissue
level. Indeed, autoreactive B lymphocytes in pSS are gen-
erated in target tissue where autoantigen release by SGECs
is massive. Only when the inflammatory infiltrate is
particularly severe can the protein be released in larger
amounts in the circulation, as supported by our finding
showing a direct correlation between level of serum
IFI16 and degree of MSG inflammatory score.
In this setting, our observations that circulating IFI16
levels were associated with RF and inversely correlated
with age at disease diagnosis are particularly intriguing.
Indeed, although we failed to identify any association
with disease activity, this finding appears to fit with the
observation that patients diagnosed at a younger age are
more likely to have circulating autoantibodies and usually
display more severe glandular inflammation [2, 24, 25].Conclusion
In conclusion, although we are aware that our study dis-
plays some limitations due to its retrospective nature
and the low number of patients, we believe that our re-
sults may shed some light on the role of IFN-inducible
genes in pSS pathogenesis. Larger and prospective
studies, however, are required to point out a possible
application of serum IFI16 protein detection in the current
clinical practice.Abbreviations
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